{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:32:08Z","timestamp":1793025128667,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Decompensated liver cirrhosis (DLC) is characterized by severe liver dysfunction and immune dysregulation, posing significant treatment challenges. Mesenchymal stromal cell (MSC) therapy has shown promise in DLC treatment, but the optimal dosing strategies and dose-dependent therapeutic mechanisms in humans remain unclear, limiting its clinical application. We conducted sequential Phase Ia\/Ib trials using a single-arm, dose-escalation design to evaluate the safety and tolerability of MSC therapy in DLC patients while also exploring its immunomodulatory effects and gathering preliminary therapeutic signals. In Phase Ia, four dose cohorts received a single dose of MSCs: 5.0\u2009\u00d7\u200910\u2077, 1.0\u2009\u00d7\u200910\u2078, 1.5\u2009\u00d7\u200910\u2078, and 2.0\u2009\u00d7\u200910\u2078 cells. Patients were followed up on Days 3, 7, 14, and 28. Multiomics analyses, including single-cell RNA sequencing and cytometry by time of flight, were conducted to perform exploratory mechanistic analyses investigating immune cell dynamics and dose-dependent responses. Building on these findings, Phase Ib included two dose cohorts, each of which received three doses of MSCs administered one week apart: 1.0\u2009\u00d7\u200910\u2078 and 2.0\u2009\u00d7\u200910\u2078 cells per dose. Patients were followed up on Days 7, 14, 21, and 28 to further evaluate the safety and feasibility of multiple-dose regimens. The trials were registered at ClinicalTrials.gov (NCT05227846 and NCT05984303). MSC therapy demonstrated good safety and tolerability in both Phase Ia and Phase Ib trials, with no severe adverse events, dose-limiting toxicities, or serious unexpected adverse reactions observed up to Day 28. Multi-omics analyses revealed that higher MSC doses elicited stronger immunomodulatory effects, particularly by modulating monocyte subsets. In particular, myxovirus resistance 1 positive (MX1\n                    <jats:sup>+<\/jats:sup>\n                    ) monocytes, a key monocyte population, exhibited dose-dependent changes and were identified as a mediator of MSC-induced immunomodulation. These effects were sustained for up to seven days post-treatment but diminished by Day 14. Preliminary clinical signals included improvements in Child\u2013Pugh scores, Model for End-Stage Liver Disease scores, liver function markers, and quality-of-life metrics, particularly in the higher-dose and multiple-dose groups. This study demonstrates the safety and tolerability of MSC therapy in patients with DLC and provides the first human-based evidence on the dose\u2012effect relationship and optimal administration regimens. The identification of MX1\n                    <jats:sup>+<\/jats:sup>\n                    monocytes as a critical mediator highlights the potential of MSC therapy to modulate immune dysfunction in DLC. These findings offer valuable insights for optimizing MSC therapy and informing the design of future efficacy-focused clinical trials.\n                  <\/jats:p>","DOI":"10.1038\/s41392-025-02318-4","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T23:01:56Z","timestamp":1753743716000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Dose-escalation studies of mesenchymal stromal cell therapy for decompensated liver cirrhosis: phase Ia\/Ib results and immune modulation insights"],"prefix":"10.1038","volume":"10","author":[{"given":"Lei","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0426-2467","authenticated-orcid":false,"given":"Song","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zerui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqi","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuefei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaidi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanglin","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengyun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanping","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8318-6888","authenticated-orcid":false,"given":"Jun-Liang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8126-8145","authenticated-orcid":false,"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonggang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Fen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6218-1885","authenticated-orcid":false,"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8043-6685","authenticated-orcid":false,"given":"Fu-Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"key":"2318_CR1","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/S0140-6736(21)01374-X","volume":"398","author":"P Gines","year":"2021","unstructured":"Gines, P. et al. Liver cirrhosis. Lancet 398, 1359\u20131376 (2021).","journal-title":"Lancet"},{"key":"2318_CR2","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","volume":"20","author":"DQ Huang","year":"2023","unstructured":"Huang, D. Q. et al. Global epidemiology of cirrhosis - aetiology, trends and predictions. Nat. Rev. Gastroenterol. Hepatol. 20, 388\u2013398 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2318_CR3","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.jhep.2014.08.010","volume":"61","author":"A Albillos","year":"2014","unstructured":"Albillos, A., Lario, M. & Alvarez-Mon, M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J. Hepatol. 61, 1385\u20131396 (2014).","journal-title":"J. Hepatol."},{"key":"2318_CR4","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41575-021-00520-7","volume":"19","author":"A Albillos","year":"2022","unstructured":"Albillos, A. et al. Cirrhosis-associated immune dysfunction. Nat. Rev. Gastroenterol. Hepatol. 19, 112\u2013134 (2022).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2318_CR5","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/HEP.0000000000000907","volume":"81","author":"R Feio-Azevedo","year":"2025","unstructured":"Feio-Azevedo, R. et al. Distinct immunometabolic signatures in circulating immune cells define disease outcome in acute-on-chronic liver failure. Hepatology 81, 509\u2013522 (2025).","journal-title":"Hepatology"},{"key":"2318_CR6","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","volume":"20","author":"L Hammerich","year":"2023","unstructured":"Hammerich, L. & Tacke, F. Hepatic inflammatory responses in liver fibrosis. Nat. Rev. Gastroenterol. Hepatol. 20, 633\u2013646 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2318_CR7","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jhep.2020.11.048","volume":"74","author":"V Arroyo","year":"2021","unstructured":"Arroyo, V. et al. The systemic inflammation hypothesis: towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. J. Hepatol. 74, 670\u2013685 (2021).","journal-title":"J. Hepatol."},{"key":"2318_CR8","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1002\/hep.28740","volume":"64","author":"J Claria","year":"2016","unstructured":"Claria, J. et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatology 64, 1249\u20131264 (2016).","journal-title":"Hepatology"},{"key":"2318_CR9","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jhep.2020.03.027","volume":"73","author":"C Bernsmeier","year":"2020","unstructured":"Bernsmeier, C., van der Merwe, S. & Perianin, A. Innate immune cells in cirrhosis. J. Hepatol. 73, 186\u2013201 (2020).","journal-title":"J. Hepatol."},{"key":"2318_CR10","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1136\/gutjnl-2017-314240","volume":"67","author":"J Fernandez","year":"2018","unstructured":"Fernandez, J. et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut 67, 1870\u20131880 (2018).","journal-title":"Gut"},{"key":"2318_CR11","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1111\/liv.12520","volume":"34","author":"T Gustot","year":"2014","unstructured":"Gustot, T. et al. Impact of infection on the prognosis of critically ill cirrhotic patients: results from a large worldwide study. Liver Int. 34, 1496\u20131503 (2014).","journal-title":"Liver Int."},{"key":"2318_CR12","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41392-022-01134-4","volume":"7","author":"DM Hoang","year":"2022","unstructured":"Hoang, D. M. et al. Stem cell-based therapy for human diseases. Signal Transduct. Target. Ther. 7, 272 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2318_CR13","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.jhep.2018.01.030","volume":"68","author":"M Alfaifi","year":"2018","unstructured":"Alfaifi, M., Eom, Y. W., Newsome, P. N. & Baik, S. K. Mesenchymal stromal cell therapy for liver diseases. J. Hepatol. 68, 1272\u20131285 (2018).","journal-title":"J. Hepatol."},{"key":"2318_CR14","doi-asserted-by":"publisher","first-page":"S157","DOI":"10.1016\/j.jhep.2015.02.040","volume":"62","author":"SJ Forbes","year":"2015","unstructured":"Forbes, S. J., Gupta, S. & Dhawan, A. Cell therapy for liver disease: from liver transplantation to cell factory. J. Hepatol. 62, S157\u2013S169 (2015).","journal-title":"J. Hepatol."},{"key":"2318_CR15","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jhep.2013.01.018","volume":"59","author":"Z Zhang","year":"2013","unstructured":"Zhang, Z. & Wang, F. S. Stem cell therapies for liver failure and cirrhosis. J. Hepatol. 59, 183\u2013185 (2013).","journal-title":"J. Hepatol."},{"key":"2318_CR16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s13287-023-03494-2","volume":"14","author":"H Wang","year":"2023","unstructured":"Wang, H. et al. Meta-analysis on last ten years of clinical injection of bone marrow-derived and umbilical cord MSC to reverse cirrhosis or rescue patients with acute-on-chronic liver failure. Stem Cell Res. Ther. 14, 267 (2023).","journal-title":"Stem Cell Res. Ther."},{"key":"2318_CR17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41423-023-00983-5","volume":"20","author":"X Yang","year":"2023","unstructured":"Yang, X. et al. Mesenchymal stromal cells in hepatic fibrosis\/cirrhosis: from pathogenesis to treatment. Cell Mol. Immunol. 20, 583\u2013599 (2023).","journal-title":"Cell Mol. Immunol."},{"key":"2318_CR18","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/stcltm\/szac053","volume":"11","author":"TT Li","year":"2022","unstructured":"Li, T. T. et al. Stem Cell Therapies for Chronic Liver Diseases: Progress and Challenges. Stem Cells Transl. Med. 11, 900\u2013911 (2022).","journal-title":"Stem Cells Transl. Med."},{"key":"2318_CR19","doi-asserted-by":"publisher","first-page":"244","DOI":"10.5152\/tjg.2015.0074","volume":"26","author":"M Kantarcioglu","year":"2015","unstructured":"Kantarcioglu, M. et al. Efficacy of autologous mesenchymal stem cell transplantation in patients with liver cirrhosis. Turk. J. Gastroenterol. 26, 244\u2013250 (2015).","journal-title":"Turk. J. Gastroenterol."},{"key":"2318_CR20","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1111\/liv.12228","volume":"33","author":"M Mohamadnejad","year":"2013","unstructured":"Mohamadnejad, M. et al. Randomized placebo-controlled trial of mesenchymal stem cell transplantation in decompensated cirrhosis. Liver Int. 33, 1490\u20131496 (2013).","journal-title":"Liver Int."},{"key":"2318_CR21","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.stem.2022.10.001","volume":"29","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Reciprocal regulation of mesenchymal stem cells and immune responses. Cell Stem Cell 29, 1515\u20131530 (2022).","journal-title":"Cell Stem Cell"},{"key":"2318_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.833878","volume":"13","author":"R Wu","year":"2022","unstructured":"Wu, R. et al. Mesenchymal stem cell-derived extracellular vesicles in liver immunity and therapy. Front. Immunol. 13, 833878 (2022).","journal-title":"Front. Immunol."},{"key":"2318_CR23","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.jhep.2014.10.030","volume":"62","author":"RP Meier","year":"2015","unstructured":"Meier, R. P. et al. Microencapsulated human mesenchymal stem cells decrease liver fibrosis in mice. J. Hepatol. 62, 634\u2013641 (2015).","journal-title":"J. Hepatol."},{"key":"2318_CR24","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1097\/HEP.0000000000000831","volume":"81","author":"X Feng","year":"2024","unstructured":"Feng, X. et al. Mesenchymal stem cells alleviate mouse liver fibrosis by inhibiting pathogenic function of intrahepatic B cells. Hepatology 81, 1211\u20131227 (2024).","journal-title":"Hepatology"},{"key":"2318_CR25","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1111\/jgh.12653","volume":"29","author":"L Xu","year":"2014","unstructured":"Xu, L. et al. Randomized trial of autologous bone marrow mesenchymal stem cells transplantation for hepatitis B virus cirrhosis: regulation of Treg\/Th17 cells. J. Gastroenterol. Hepatol. 29, 1620\u20131628 (2014).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"2318_CR26","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1136\/gutjnl-2017-314184","volume":"67","author":"C Bernsmeier","year":"2018","unstructured":"Bernsmeier, C. et al. CD14(+) CD15(-) HLA-DR(-) myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure. Gut 67, 1155\u20131167 (2018).","journal-title":"Gut"},{"key":"2318_CR27","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1002\/hep.28693","volume":"64","author":"KT Suk","year":"2016","unstructured":"Suk, K. T. et al. Transplantation with autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: phase 2 trial. Hepatology 64, 2185\u20132197 (2016).","journal-title":"Hepatology"},{"key":"2318_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/hep.29189","volume":"66","author":"B-l Lin","year":"2017","unstructured":"Lin, B. -l. et al. Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial. Hepatology 66, 209\u2013219 (2017).","journal-title":"Hepatology"},{"key":"2318_CR29","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1440-1746.2011.07024.x","volume":"27","author":"Z Zhang","year":"2012","unstructured":"Zhang, Z. et al. Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. J. Gastroenterol. Hepatol. 27, 112\u2013120 (2012).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"2318_CR30","doi-asserted-by":"publisher","first-page":"725","DOI":"10.5966\/sctm.2012-0034","volume":"1","author":"M Shi","year":"2012","unstructured":"Shi, M. et al. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem Cells Transl. Med. 1, 725\u2013731 (2012).","journal-title":"Stem Cells Transl. Med."},{"key":"2318_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/jgh.12029","volume":"28","author":"L Wang","year":"2013","unstructured":"Wang, L. et al. Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis. J. Gastroenterol. Hepatol. 28, 85\u201392 (2013).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"2318_CR32","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1002\/sctm.17-0134","volume":"6","author":"M Shi","year":"2017","unstructured":"Shi, M. et al. A pilot study of mesenchymal stem cell therapy for acute liver allograft rejection. Stem Cells Transl. Med. 6, 2053\u20132061 (2017).","journal-title":"Stem Cells Transl. Med."},{"key":"2318_CR33","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ajpath.2012.03.014","volume":"181","author":"L Yang","year":"2012","unstructured":"Yang, L. et al. Bone marrow-derived mesenchymal stem cells differentiate to hepatic myofibroblasts by transforming growth factor-beta1 via sphingosine kinase\/sphingosine 1-phosphate (S1P)\/S1P receptor axis. Am. J. Pathol. 181, 85\u201397 (2012).","journal-title":"Am. J. Pathol."},{"key":"2318_CR34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13287-017-0541-2","volume":"8","author":"N Lanthier","year":"2017","unstructured":"Lanthier, N. et al. Autologous bone marrow-derived cell transplantation in decompensated alcoholic liver disease: what is the impact on liver histology and gene expression patterns?. Stem Cell Res. Ther. 8, 88 (2017).","journal-title":"Stem Cell Res. Ther."},{"key":"2318_CR35","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.bbmt.2020.01.018","volume":"26","author":"J Kurtzberg","year":"2020","unstructured":"Kurtzberg, J. et al. A phase 3, single-arm, prospective study of remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease. Biol. Blood Marrow Transpl. 26, 845\u2013854 (2020).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"2318_CR36","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1182\/blood-2011-11-391144","volume":"120","author":"J Xu","year":"2012","unstructured":"Xu, J. et al. Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sj\u00f6gren syndrome. Blood 120, 3142\u20133151 (2012).","journal-title":"Blood"},{"key":"2318_CR37","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1136\/ard.2009.123463","volume":"69","author":"J Liang","year":"2010","unstructured":"Liang, J. et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann. Rheum. Dis. 69, 1423\u20131429 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"2318_CR38","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S2468-1253(24)00078-5","volume":"9","author":"S Piano","year":"2024","unstructured":"Piano, S., Bunchorntavakul, C., Marciano, S. & Rajender Reddy, K. Infections in cirrhosis. Lancet Gastroenterol. Hepatol. 9, 745\u2013757 (2024).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"2318_CR39","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41423-023-01018-9","volume":"20","author":"C Giacomini","year":"2023","unstructured":"Giacomini, C., Graneli, C., Hicks, R. & Dazzi, F. The critical role of apoptosis in mesenchymal stromal cell therapeutics and implications in homeostasis and normal tissue repair. Cell Mol. Immunol. 20, 570\u2013582 (2023).","journal-title":"Cell Mol. Immunol."},{"key":"2318_CR40","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1016\/j.ymthe.2024.04.026","volume":"32","author":"HJ Lee","year":"2024","unstructured":"Lee, H. J. et al. Defining mesenchymal stem\/stromal cell-induced myeloid-derived suppressor cells using single-cell transcriptomics. Mol. Ther. 32, 1970\u20131983 (2024).","journal-title":"Mol. Ther."},{"key":"2318_CR41","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41418-023-01243-9","volume":"31","author":"T He","year":"2024","unstructured":"He, T. et al. The bone-liver interaction modulates immune and hematopoietic function through Pinch-Cxcl12-Mbl2 pathway. Cell Death Differ. 31, 90\u2013105 (2024).","journal-title":"Cell Death Differ."},{"key":"2318_CR42","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41392-025-02162-6","volume":"10","author":"X Zheng","year":"2025","unstructured":"Zheng, X. et al. Host FSTL1 defines the impact of stem cell therapy on liver fibrosis by potentiating the early recruitment of inflammatory macrophages. Signal Transduct. Target. Ther. 10, 81 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2318_CR43","doi-asserted-by":"publisher","first-page":"e11049","DOI":"10.1371\/journal.pone.0011049","volume":"5","author":"HW Zimmermann","year":"2010","unstructured":"Zimmermann, H. W. et al. Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS ONE 5, e11049 (2010).","journal-title":"PLoS ONE"},{"key":"2318_CR44","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/j.1478-3231.2008.01870.x","volume":"29","author":"ML Berres","year":"2009","unstructured":"Berres, M. L. et al. Longitudinal monocyte human leukocyte antigen-DR expression is a prognostic marker in critically ill patients with decompensated liver cirrhosis. Liver Int. 29, 536\u2013543 (2009).","journal-title":"Liver Int."},{"key":"2318_CR45","doi-asserted-by":"publisher","first-page":"e201900465","DOI":"10.26508\/lsa.201900465","volume":"3","author":"R Brenig","year":"2020","unstructured":"Brenig, R. et al. Expression of AXL receptor tyrosine kinase relates to monocyte dysfunction and severity of cirrhosis. Life Sci. Alliance 3, e201900465 (2020).","journal-title":"Life Sci. Alliance"},{"key":"2318_CR46","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ebiom.2019.10.011","volume":"49","author":"F Lebosse","year":"2019","unstructured":"Lebosse, F. et al. CD8(+)T cells from patients with cirrhosis display a phenotype that may contribute to cirrhosis-associated immune dysfunction. EBioMedicine 49, 258\u2013268 (2019).","journal-title":"EBioMedicine"},{"key":"2318_CR47","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.3389\/fimmu.2018.02948","volume":"9","author":"E Triantafyllou","year":"2018","unstructured":"Triantafyllou, E. et al. The role of monocytes and macrophages in acute and acute-on-chronic liver failure. Front. Immunol. 9, 2948 (2018).","journal-title":"Front. Immunol."},{"key":"2318_CR48","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1136\/gutjnl-2018-316888","volume":"68","author":"H Korf","year":"2019","unstructured":"Korf, H. et al. Inhibition of glutamine synthetase in monocytes from patients with acute-on-chronic liver failure resuscitates their antibacterial and inflammatory capacity. Gut 68, 1872\u20131883 (2019).","journal-title":"Gut"},{"key":"2318_CR49","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/HEP.0000000000000907","volume":"81","author":"R Feio-Azevedo","year":"2024","unstructured":"Feio-Azevedo, R. et al. Distinct immunometabolic signatures in circulating immune cells define disease outcome in acute-on-chronic liver failure. Hepatology 81, 509\u2013522 (2024).","journal-title":"Hepatology"},{"key":"2318_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12150","volume":"7","author":"V Bronte","year":"2016","unstructured":"Bronte, V. et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat. Commun. 7, 12150 (2016).","journal-title":"Nat. Commun."},{"key":"2318_CR51","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/hep.510250508","volume":"25","author":"FJ Laso","year":"1997","unstructured":"Laso, F. J. et al. Decreased natural killer cytotoxic activity in chronic alcoholism is associated with alcohol liver disease but not active ethanol consumption. Hepatology 25, 1096\u20131100 (1997).","journal-title":"Hepatology"},{"key":"2318_CR52","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S2213-2600(18)30508-3","volume":"7","author":"MKD Scott","year":"2019","unstructured":"Scott, M. K. D. et al. Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort study. Lancet Respir. Med. 7, 497\u2013508 (2019).","journal-title":"Lancet Respir. Med."},{"key":"2318_CR53","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1182\/bloodadvances.2022008021","volume":"7","author":"CV Edwards","year":"2023","unstructured":"Edwards, C. V. et al. Peripheral blood monocyte count is a dynamic prognostic biomarker in multiple myeloma. Blood Adv. 7, 482\u2013490 (2023).","journal-title":"Blood Adv."},{"key":"2318_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2023.103000","volume":"135","author":"R Wesselingh","year":"2023","unstructured":"Wesselingh, R. et al. Peripheral monocytes and soluble biomarkers in autoimmune encephalitis. J. Autoimmun. 135, 103000 (2023).","journal-title":"J. Autoimmun."},{"key":"2318_CR55","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587 e3529 (2021).","journal-title":"Cell"},{"key":"2318_CR56","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","volume":"8","author":"CS McGinnis","year":"2019","unstructured":"McGinnis, C. S., Murrow, L. M. & Gartner, Z. J. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 8, 329\u2013337.e324 (2019).","journal-title":"Cell Syst."},{"key":"2318_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin, S. et al. Inference and analysis of cell-cell communication using CellChat. Nat. Commun. 12, 1088 (2021).","journal-title":"Nat. Commun."},{"key":"2318_CR58","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41586-019-0969-x","volume":"566","author":"J Cao","year":"2019","unstructured":"Cao, J. et al. The single-cell transcriptional landscape of mammalian organogenesis. Nature 566, 496\u2013502 (2019).","journal-title":"Nature"},{"key":"2318_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-018-4772-0","volume":"19","author":"K Street","year":"2018","unstructured":"Street, K. et al. Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics. BMC Genom.19, 477 (2018).","journal-title":"BMC Genom."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02318-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02318-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02318-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T23:05:43Z","timestamp":1757286343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02318-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2318"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02318-4","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,29]]},"assertion":[{"value":"19 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.Q.Y. was an employee of Wuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd. Y.Z. and T.Y.D. are current employees of the same company. All the other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"238"}}